Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Ulcerative Colitis
Interventions: Basiliximab; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 25
States / cities: Anaheim, California • Roseville, California • Golden, Colorado + 22 more

Conditions: Viruria
Interventions: Placebo, Brincidofovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 10 more

Conditions: Reading
Interventions: Reading and Growth Mindset, Wait-list Control; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 9 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: Lenalidomide 15mg, Lenalidomide 25mg; Drug
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Hines, Illinois + 4 more

Conditions: Pain, Postoperative, Root Canal Infection, Endodontically Treated Teeth
Interventions: GentleWave, Conventional Protocol; Other
Lead sponsor: University of Salamanca; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Cancer
Interventions: Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Hiatal Hernia, Paraesophageal Hernia
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: St Louis, Missouri • Portland, Oregon • Seattle, Washington

Conditions: Irritable Bowel Syndrome
Interventions: 250 mg LX1033 tablets, Placebo tablet; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 81
States / cities: Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy; Biological · Drug
Lead sponsor: Genprex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more

Conditions: Chronic Pain
Interventions: BioPlete™ Advanced Formula, Placebo; Dietary Supplement
Lead sponsor: Ethos Research & Development; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • West Palm Beach, Florida

Conditions: Alcohol Drinking, Tobacco Smoking
Interventions: Media Detective; Behavioral
Lead sponsor: Innovation Research & Training; Other
Eligibility: 7 Years to 12 Years
Enrollment: 679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fibromyalgia
Interventions: milnacipran, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 6,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 107
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
Interventions: BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Dulaglutide, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more

Conditions: Schizophrenia
Interventions: Luvadaxistat, Matching Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Analgesia
Interventions: Bupivacaine Hydrochloride, HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Little Rock, Arkansas • Sarasota, Florida • Tulsa, Oklahoma + 4 more

Conditions: Pain, Postoperative
Interventions: Ketolorac; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Beachwood, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: The 3Ms Intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 15 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Chicago, Illinois • Detroit, Michigan • Royal Oak, Michigan

Conditions: Kidney Transplantation
Interventions: TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG; Biological · Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Pain, Postoperative
Interventions: Caffeine, Placebo oral tablet; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Egg Harbor, New Jersey

Conditions: Autism Spectrum Disorder, Autism
Interventions: ASSIST; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Chicago, Illinois • Nashville, Tennessee • Madison, Wisconsin

Conditions: Cancer Survivors, Chemotherapy-related Cognitive Impairment
Interventions: Neuroplasticity-based Computerized Cognitive Remediation; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Basiliximab in Moderate to Severe Ulcerative Colitis

CMX001 in Post-transplant Patients With BK Virus Viruria

Ready to Read: Ready to Read: A School-Based Intervention to Promote Growth Mindset and Reading

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Effectiveness of GentleWave System in Endodontic Treatment

Decision Making for Older Adults With Cancer

Study of Paraesophageal Hernia Repair With Small Intestine Submucosa

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

Evaluation of the Media Detective Program for Elementary School-Aged Children to Prevention Substance Use

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Intra Uterine Device Insertion in Nulliparous Women

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

Ketolorac Versus Saline at Laparoscopic Incision Sites

Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)

A Dose Escalation Study in de Novo Renal Transplantation

Caffeine Study for Pain Control Following Total Joint Replacement

Advocating for Supports to Improve Service Transitions

Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment